Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan W Partin

Showing results (51-60 of 349) with videos related to

Pageof 35
Sort By:
Reviews in Urology|September 21, 2006
Prostate cancer update: 2004: highlights from the 4th international prostate cancer congress, grand bahama island, bahamas, july 15-18, 2004Stephen J Freedland, Alan W Partin
Journal of the National Comprehensive Cancer Network : JNCCN|October 3, 2009
Prostate cancer early detection clinical practice guidelines in oncologyRichard J Babaian, Alan W Partin,
The Oncologist|May 30, 2003
Management of high-risk populations with locally advanced prostate cancerMasood A Khan, Alan W Partin
Reviews in Urology|July 29, 2008
Weighing the risks: prostate cancer versus cardiovascular diseaseDanil V Makarov, Alan W Partin
Reviews in Urology|April 30, 2010
Complications of pelvic lymphadenectomy: do the risks outweigh the benefits?Stacy Loeb, Alan W Partin, Edward M Schaeffer
Urology|August 10, 2010
Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosisFadi Brimo, Alan W Partin, Jonathan I Epstein
The Journal of Urology|July 20, 2002
Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. rangeAlexander Haese, Robert T Dworschack, Alan W Partin
Reviews in Urology|April 25, 2009
Robotic image-guided needle interventions of the prostatePierre C Mozer, Alan W Partin, Dan Stoianovici
Reviews in Urology|October 18, 2006
The importance of pelvic lymph node dissection in men with clinically localized prostate cancerMohamad E Allaf, Alan W Partin, H Ballentine Carter
Therapeutic Advances in Urology|December 2, 2015
Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic riskJason E Michaud, Kevin L Billups, Alan W Partin
Pageof 35

Showing results (51-60 of 349) with videos related to

Sort By:
Pageof 35
Reviews in Urology|September 21, 2006
Prostate cancer update: 2004: highlights from the 4th international prostate cancer congress, grand bahama island, bahamas, july 15-18, 2004Stephen J Freedland, Alan W Partin
Journal of the National Comprehensive Cancer Network : JNCCN|October 3, 2009
Prostate cancer early detection clinical practice guidelines in oncologyRichard J Babaian, Alan W Partin,
The Oncologist|May 30, 2003
Management of high-risk populations with locally advanced prostate cancerMasood A Khan, Alan W Partin
Reviews in Urology|July 29, 2008
Weighing the risks: prostate cancer versus cardiovascular diseaseDanil V Makarov, Alan W Partin
Reviews in Urology|April 30, 2010
Complications of pelvic lymphadenectomy: do the risks outweigh the benefits?Stacy Loeb, Alan W Partin, Edward M Schaeffer
Urology|August 10, 2010
Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosisFadi Brimo, Alan W Partin, Jonathan I Epstein
The Journal of Urology|July 20, 2002
Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. rangeAlexander Haese, Robert T Dworschack, Alan W Partin
Reviews in Urology|April 25, 2009
Robotic image-guided needle interventions of the prostatePierre C Mozer, Alan W Partin, Dan Stoianovici
Reviews in Urology|October 18, 2006
The importance of pelvic lymph node dissection in men with clinically localized prostate cancerMohamad E Allaf, Alan W Partin, H Ballentine Carter
Therapeutic Advances in Urology|December 2, 2015
Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic riskJason E Michaud, Kevin L Billups, Alan W Partin
Pageof 35